Audentes Therapeutics Garners $42,500,000 Series B Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ab240430-bac8-4099-b0d6-e4016c5cbf91
Date
12/3/2014
Company Name
Audentes Therapeutics
Mailing Address
101 Montgomery Street. San Francisco, CA 94104 USA
Company Description
Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology.
Website
http://www.audentestx.com
Transaction Type
Venture Equity
Transaction Amount
$42,500,000
Transaction Round
Series B
Proceeds Purposes
The additional funding will allow Audentes to achieve key clinical development milestones for its two lead programs and to continue research and in-licensing efforts to become a worldwide leader in gene therapy.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor